TransCure bioServices welcomes Cathay Capital to accelerate ambitious growth

TransCure bioServices

June 29, 2022

Archamps, June 29th, 2022 – Cathay Capital announces its investment in TransCure bioServices, alongside the management team and Financière Arbevel. With this transaction, TransCure bioServices will benefit from Cathay Capital’s healthcare expertise as well as its strategic and financial support to accelerate growth and global expansion.

Founded in 2012 and based in Archamps (Haute-Savoie, France), TransCure bioServices is a leading “one-stop-shop” preclinical contract research organization (CRO). Specializing in advanced preclinical in vivo pharmacology with mouse models of fully reconstituted human immune system (HIS) or human-liver (Hu-liver), the company addresses various therapeutic areas including immuno-oncology, infectious diseases and inflammatory auto-immune diseases. Thanks to unique scientific expertise and proprietary humanization techniques, along with a track-record of data accumulated over the course of 10+ years, TransCure bioServices has developed unrivaled quality of services for a large and international customer base, providing c.70 large pharmas and biotech companies with the full spectrum of analytical testing.
TransCure capitalizes on fully reconstituted human immune system and hepatic disease models with humanization rates that overperform market standards — allowing for test results reliability comparable to clinical study outcomes. With 80 employees, including 20 PhDs, the company has witnessed double-digit organic growth over the last several years reaching more than €10m of revenue and has recently been awarded the AAALAC certification.
With strong experience in the healthcare sector and powered by its global platform, Cathay Capital’s investment will support TransCure bioServices in its next development phase, notably to accelerate international expansion, develop new mice model platforms, increase production capacities, as well as strengthen the team and execute a focused external growth strategy.

Patrick Nef, PhD, co-founder and CEO of TransCure bioServices, said: “We have experienced a very high growth rate over the past 5-years, becoming a truly global leading and highly specialized CRO in predictive in vivo pharmacology with humanized mouse models. Today, we welcome Cathay Capital as a timely and natural partner for us as we start the next phase of our next journey, benefitting from their experience in healthcare and know-how in accompanying fast-growing companies internationally.” 

Fabien Wesse, Managing Partner at Cathay Capital, added: “We are very happy to work with Patrick Nef, Sébastien Tabruyn and the management team to support them in the company’s ambitious project. TransCure bioServices benefits from unique scientific expertise on humanized mouse models across a variety of therapeutic areas, in a highly specialized rapidly growing preclinical market. We are delighted that they have chosen Cathay as partners and look forward to accompanying their growth by leveraging our global platform, ecosystem, and long-standing commitment to the healthcare industry.” 

About TransCure bioServices SAS

TransCure bioServices SAS is a European CRO based in France offering preclinical predictive in vivo pharmacology testing services to international large pharmaceutical, biotech and academic customers. Uniquely designed preclinical models with functional human immune system and human hepatocytes/liver provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV, Dengue), liver diseases, vaccines, and immuno-hepato toxicity (DMPK, ADME). If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver, contact us at

About Cathay Capital 

Cathay Capital Group is a global investment firm supporting companies at all stages throughout North America, Asia, Europe and Africa. By helping navigate the opportunities of globalization and sustainable transformation, Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its global platform connects people – from investors and entrepreneurs to management teams and leading corporations – across continents to share knowledge, the tools to scale, and achieve the extraordinary. Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages more than $4.5 billion in assets, has completed over 220 buyouts, growth and venture capital investments with the global reach and local expertise from offices in Paris, New York, Shanghai, Munich, San Francisco, Beijing, Singapore, Shenzhen and Tel Aviv.